|
| ||
|
|
5/13/2006
NPLAC Renews Appeal to FDA to Remove Deadly Abortion Pill, RU-486, from Market WASHINGTON, May 11 /Christian Newswire/ -- National Pro-Life Action Center (NPLAC)—the uncompromising voice of pro-life America on Capitol Hill—renewed its plea to remove RU-486 (also know as Mifeprex and Mifepristone) from the market in response to news that the Food and Drug Administration (FDA) will hold a high-profile meeting today about deadly side-effects associated with the drug’s use. “RU-486 is a lethal drug regimen that takes the life of an innocent unborn child every time—and in many cases has taken the life of the mother as well,” said Paul Chaim Schenck, director of NPLAC. “Given the number of deaths known or suspected to be associated with RU-486, and given the knowledge that many organizations, like Planned Parenthood, have been dispensing it with improper use instructions, the FDA would be guilty of gross negligence if they do not immediately remove RU-486 from the market.” “No less than five women have died as a direct result of using this drug, yet the FDA seems content to continue ‘dialoguing’ about how to handle this ‘situation,’ while abortionists continue to prescribe this hazardous drug to unsuspecting women,” stated Stephen G. Peroutka, Esq., NPLAC chairman, regarding the meeting to be held jointly with the Centers for Disease Control (CDC), and the National Institute of Allergy and Infectious Diseases at the CDC’s Atlanta campus, which will focus on scientific questions about the infection Clostridium sordellii, that has led to the death of several women taking the chemical abortion regimen . “As far as RU-486 is concerned, the FDA’s initial failure occurred when the agency approved this drug for use; if the agency neglects to take immediate and decisive action to remove this deadly substance from the market, it will have utterly failed its mandate to act in the best interest of the public health and safety.” “At a time when the integrity and efficacy of the FDA is under increased scrutiny for allegations of preferential treatment in the approval process, financial improprieties and other abuses of the regulatory system, it would be in the best interest of the agency to properly redress this problem,” said Schenck. Schenck’s comments are in response to recent revelations that the former FDA director is under criminal investigation for misconduct and questions surrounding the fast-track approval of several prescription drugs that were later removed from the market because they proved too dangerous for use. “If the FDA were serious about this tragedy, they would admit their mistake, remove the drug from the market and take a serious look at the medical research—like that of Dr. Donna Harrison, chairman of the subcommittee on Mifeprex of AAPLOG—that clearly demonstrates that this drug is responsible for an exponentially higher number of deaths than originally believed,” concluded Peroutka.
| |
|
| ||
